Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2020-09-29 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2020-09-29 English
News release - English.pdf
Regulatory Filings
2020-08-31 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical evaluation study results for a COVID-19 antigen test developed by Sona Nanotech. It contains no financial data, no regulatory filings, no shareholder meeting information, no management or board changes, no earnings or financial results, and no detailed investor presentation. It is a product and clinical study announcement, which does not fit into any of the specific financial or regulatory filing categories. It is a general corporate announcement about product development and clinical results. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2020-08-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expected release of clinical in-field validation study results for a COVID-19 antigen test by Sona Nanotech. It mentions that the report will be released next week and provides background on the company and cautionary statements. The document does not contain actual financial data, detailed study results, or substantive analysis. It is an announcement about a forthcoming report rather than the report itself. The length is under 5,000 characters and it serves as a market update and forward-looking statement. Therefore, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2020-08-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings, signed by the Interim CEO, certifying the accuracy and fairness of the interim financial report and interim MD&A for the period ending June 30, 2020. It is primarily an officer certification letter confirming the integrity of the interim filings rather than the filings themselves. The document length is short (3334 characters) and contains no actual financial data or substantive financial analysis. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2020-08-06 English
News release - English.pdf
Regulatory Filings
2020-07-23 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.